sur Jaguar Health, Inc. (NASDAQ:JAGX)
Ladenburg Thalmann to Host Scientific Showcase on Jaguar Health's Crofelemer
Ladenburg Thalmann will host a virtual Scientific Showcase on December 18, 2024, dedicated to clinical development efforts for Jaguar Health's Crofelemer. This event will examine Crofelemer, a plant-based anti-diarrheal drug, with a focus on rare diseases like microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF). Currently, five clinical initiatives are in progress across different regions, including the US and Europe. Significant proof-of-concept results are anticipated by Q2 2025.
The event will feature insights from Jaguar Health's leadership, including CEO Lisa Conte and Chief Scientific Officer Pravin Chaturvedi. Registration for this event, aimed at the financial and business community, is now open. Jaguar Health's efforts in expanding Crofelemer access in Europe were recently recognized, with Massimo Radaelli, CEO of Jaguar's Napo Therapeutics, receiving industry accolades.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Jaguar Health, Inc.